Business Context and Reporting Period
This Form 8-K, filed on April 20, 2012, reports a material definitive agreement entered into by Accuray Incorporated ("Accuray") with Compact Particle Acceleration Corporation ("CPAC"). CPAC, established in 2008 by TomoTherapy (a wholly-owned subsidiary of Accuray), is developing a compact proton therapy system. The filing details a preferred stock financing, debt conversions, and restructuring of licensing and shareholder agreements.
Key Financial Metrics and Transaction Details
- Equity Investment: Accuray invested $1,100,000 at the initial closing for Series A Preferred Stock and warrants. The total commitment ranges from $1,100,000 to $1,825,000.
- Debt Conversion: Approximately $1,326,000 in principal and interest from bridge loan convertible promissory notes held by Accuray and TomoTherapy was converted into Series A and Series A-1 Preferred Stock.
- Revolving Note: A $1,900,000 revolving promissory note issued by CPAC to TomoTherapy was amended to extend the maturity date to December 31, 2012. Accuray holds the right to convert this note into Series A Preferred Stock until September 30, 2012.
- Ownership Stake: Following the initial closing, Accuray owns approximately 14.1% of CPAC's outstanding stock (16.3% fully diluted). Upon completion of the financing, ownership is expected to range between 16.5% and 17.9% outstanding (18.2% to 19.0% fully diluted).
- Accounting Treatment: Accuray intends to continue consolidating CPAC in its financial statements as the primary beneficiary of the variable interest entity.
Material Changes and Agreements
- Shareholder Agreement: Accuray secured the right to designate a board member and a board observer. Accuray also obtained an option to acquire CPAC or enter a supply/distribution agreement upon specific triggers (technical milestones or board approval of an acquisition).
- Licensing Restructure: An Amended and Restated Limited Exclusive Sublicense and Cross-License Agreement was executed, clarifying royalty payments and assigning TomoTherapy's right of first refusal to CPAC for expanding the Field of Use with Lawrence Livermore National Security, LLC ("LLNS").
- Service Termination: The arrangement for TomoTherapy to provide accounting and back-office support to CPAC is scheduled to terminate by June 30, 2012.
- Previous Option Termination: Accuray's prior option to purchase CPAC stock in exchange for commercialization rights was terminated.
Outlook, Risks, and Contingencies
The filing contains forward-looking statements regarding the transaction structure, investment amounts, and potential acquisition of CPAC. Key risks include the satisfaction of closing conditions, CPAC's ability to raise additional equity from third parties, and the failure to realize anticipated benefits. The securities offered are unregistered under the Securities Act of 1933. Accuray notes that if a second closing occurs, the revolving note interest rate may decrease from 12% to 8% per annum, and the maturity date could extend to December 31, 2015, contingent on ownership caps.
Investor Verification Checklist
- Verify the final ownership percentage of Accuray in CPAC after the completion of the ongoing preferred stock financing.
- Confirm whether the second closing of the financing occurs, which would trigger mandatory conversion of the $1,900,000 revolving note (subject to the 19% ownership cap).
- Monitor the status of the termination of back-office support services by June 30, 2012.
- Review future filings for updates on the exercise of Accuray's option to acquire CPAC or enter a supply agreement.
- Check for any changes in the consolidation status of CPAC in Accuray's financial statements.